Sepsis Research Analysis
March 2026 sepsis research converged on deployable precision care and host-directed immunomodulation. A large phase 3 RCT showed that procalcitonin-guided ED assessment reduced 28-day mortality, while a prospective 1-hour IL-6/sTNFR1 plus bicarbonate panel operationalized bedside ARDS subphenotyping. A validated three-biomarker ML score (PCT, sTREM-1, IL-6) quantified immune dysregulation and identified hydrocortisone-responsive patients. Mechanistic studies nominated druggable host pathways—STA
Summary
March 2026 sepsis research converged on deployable precision care and host-directed immunomodulation. A large phase 3 RCT showed that procalcitonin-guided ED assessment reduced 28-day mortality, while a prospective 1-hour IL-6/sTNFR1 plus bicarbonate panel operationalized bedside ARDS subphenotyping. A validated three-biomarker ML score (PCT, sTREM-1, IL-6) quantified immune dysregulation and identified hydrocortisone-responsive patients. Mechanistic studies nominated druggable host pathways—STAT1 downstream of MRSA PSMα3 (with fludarabine benefit), the ERβ–FAO–STOML2 acetylation axis, and CLSTN3-mediated control of TLR N-glycosylation—pointing to biologically stratified immunotherapy.
Selected Articles
1. Targeting phenol-soluble modulin α3-driven M1 macrophage polarization and necroptosis mitigates MRSA infection in mice.
Mechanistic preclinical work shows MRSA virulence factor PSMα3 drives M1 macrophage polarization and necroptosis through an ISGF3–necrosome axis downstream of FPR2. Pharmacologic inhibition of STAT1 with the approved drug fludarabine reduced MRSA burden and improved outcomes in murine sepsis and pneumonia models, supporting host-directed anti-virulence strategies.
Impact: Identifies a targetable host–pathogen signaling axis and demonstrates efficacy with a repurposed clinically available drug in sepsis-relevant models, accelerating translational prospects.
Clinical Implications: Supports development of adjunctive, anti-virulence therapies for MRSA sepsis; next steps should define safety, dosing, and patient selection biomarkers (e.g., PSMα3 activity) before human trials.
Key Findings
- PSMα3 promotes M1 macrophage polarization and necroptosis via an ISGF3–necrosome interaction.
- FPR2 functions as the receptor mediating PSMα3 effects.
- STAT1 inhibition with fludarabine mitigated MRSA infection in murine sepsis and pneumonia models.
2. Procalcitonin testing combined with NEWS2 evaluation compared with usual care based on NEWS2 for identification of sepsis and antibiotic initiation in the emergency department in England and Wales (PRONTO): a multicentre, randomised, controlled, open-label, phase 3 trial.
A large pragmatic multicentre RCT (n=7,667) found that adding rapid procalcitonin testing to NEWS2 did not change 3-hour IV antibiotic initiation but reduced 28-day mortality (13.6% vs 16.6%). The procalcitonin result influenced clinician decisions in ~65% of cases, indicating potential mortality benefit from biomarker-guided triage independent of immediate antibiotic timing.
Impact: Provides phase 3 evidence that biomarker-guided ED assessment can reduce mortality, supporting immediate workflow changes in triage and stewardship.
Clinical Implications: Implementation of near-patient procalcitonin alongside NEWS2 in EDs should be considered, with evaluation of adherence, antibiotic duration/de-escalation, and outcome impact.
Key Findings
- No difference in 3-hour IV antibiotic initiation (48.4% vs 48.2%).
- Lower 28-day mortality with PCT-guided care (13.6% vs 16.6%; adjusted risk difference −3.12%).
- PCT influenced clinical decisions in ~64.7% of cases; adverse events similar between groups.
3. Quantifying immune dysregulation in pneumonia and sepsis with a parsimonious machine-learning model: a multicohort analysis across care settings and reanalysis of a hydrocortisone randomised controlled trial.
The authors derived and externally validated a parsimonious three-biomarker ML framework (procalcitonin, soluble TREM-1, IL-6) that reproduces an immune dysregulation continuum (DIP/cDIP) originally defined by 35 biomarkers. The 3-marker model predicted dysregulation with high accuracy across five external cohorts and showed that only severely dysregulated patients derived a survival benefit from hydrocortisone in a post-hoc RCT reanalysis.
Impact: Delivers a validated, pragmatic biomarker tool to operationalize immune-status measurement and identify likely responders to immunomodulators, enabling precision trials and bedside stratification.
Clinical Implications: Incorporate PCT, sTREM-1, and IL-6-based scoring to stratify patients for immunomodulatory therapies (e.g., hydrocortisone) and enrich trials; prospective validation in sepsis-specific RCTs is warranted.
Key Findings
- Three-biomarker model predicted DIP stages with 91.2% accuracy compared with a 35-marker reference.
- Higher cDIP scores were independently associated with mortality and secondary infections.
- Hydrocortisone reduced mortality only in severely dysregulated patients (DIP3 or cDIP ≥0.63).
4. Estrogen receptor β deficiency increases susceptibility to sepsis through metabolic reprogramming-induced macrophage pyroptosis.
This study shows reduced ERβ expression in sepsis patients and demonstrates that ERβ deficiency drives fatty-acid-oxidation–linked increases in acetyl-CoA and Stoml2 K221 acetylation, causing mitochondrial dysfunction and macrophage pyroptosis. Genetic mutation of Stoml2 K221 rescued mitochondrial function and improved survival in septic mice, linking a host genetic/metabolic axis to sepsis susceptibility and suggesting actionable targets.
Impact: Identifies an ERβ–immunometabolism–pyroptosis axis with in vivo rescue, offering biomarker and therapeutic leads (ERβ modulation, FAO/acetylation inhibitors) for personalized sepsis care.
Clinical Implications: Assess ERβ as a susceptibility/prognostic biomarker and prioritize translational work on selective ERβ modulators or FAO/acetylation pathway inhibitors to prevent macrophage pyroptosis in high-risk patients.
Key Findings
- ERβ expression is reduced in sepsis and inversely correlates with severity.
- ERβ deficiency increases FAO, acetyl-CoA, and Stoml2 K221 acetylation, driving mitochondrial dysfunction and macrophage pyroptosis.
- Mutating Stoml2 K221 mitigates pyroptosis and improves survival in septic mice.
5. Calsyntenin-3 suppresses inflammation via inhibition of TLR N-glycosylation and membrane localization.
A genome-wide CRISPR screen identified CLSTN3 as an endogenous inhibitor of TLR-driven inflammation. CLSTN3 binds DDOST, disrupts DDOST–STT3A interaction, impairs OST assembly, and reduces N-glycosylation and membrane translocation of TLR4 (and other TLRs), broadly dampening innate signaling—revealing TLR glycosylation as a modifiable control point.
Impact: Uncovers a cross-TLR, druggable checkpoint—N-glycosylation control of TLR trafficking—positioning the CLSTN3–OST axis as a novel target to temper hyperinflammation in sepsis.
Clinical Implications: Develop therapeutics that modulate TLR N-glycosylation or mimic CLSTN3 function to reduce excessive innate activation in sepsis; requires in vivo sepsis-model validation and safety profiling.
Key Findings
- Genome-wide CRISPR screen identified CLSTN3 as a suppressor of TLR4-triggered inflammation.
- CLSTN3 binds DDOST and impairs DDOST–STT3A interaction, reducing OST assembly and TLR N-glycosylation.
- Reduced N-glycosylation limits membrane localization and activation of multiple TLRs, broadly damping innate signaling.